✨ Free AI Report
VYNE Therapeutics Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research VYNE Therapeutics Inc.
Company Research

VYNE Therapeutics Inc.: Business Overview, Financials & Competitive Analysis

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a to...

Analyst-debate audio for VYNE Therapeutics Inc.

AskCyborg analysts argue the bull and bear cases for VYNE Therapeutics Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Challenged

Cyborg Score thesis

High-risk clinical-stage biotech with failed lead program and regulatory hurdles, now pursuing merger exit to preserve...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Immunology & Inflammation / Dermatology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest VYNE Therapeutics Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

VYNE Therapeutics Inc. Overview

Pro stress-test →

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug. The company has undergone significant portfolio challenges in 2025 and initiated a strategic review.

Strategic Profile

Pro stress-test →

VYNE also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. However, the company faces significant headwinds: repibresib missed primary endpoints in Phase 2b vitiligo trials, and VYN202 faced FDA clinical holds related to toxicology concerns. VYNE entered a definitive all-stock merger with Yarrow Bioscience, with the combined company expected to operate as Yarrow Bioscience and trade on Nasdaq as YARW, with RTW Investments committing approximately $200 million in pre-closing financing.

Competitive Landscape

Pro stress-test →

VYNE competes in the topical and oral inflammatory disease treatment space. Direct competitors include companies like Repare Therapeutics, Century Therapeutics, PMV Pharmaceuticals, Neuphoria Therapeutics, and other clinical-stage immunology-focused biotechs. VYNE's BET inhibitor approach represents a differentiated mechanism, though recent clinical failures have significantly weakened its competitive position.

Industry Context

VYNE Therapeutics Inc. operates in Biopharmaceuticals - Immunology & Inflammation / Dermatology.

Key facts

Founded: 2003 · Headquarters: Bridgewater, New Jersey · Revenue: $501K (2024)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on VYNE Therapeutics Inc..

  • Repibresib (VYN201) Phase 2b vitiligo trial failed primary and key secondary endpoints; company terminating extension phase and seeking external partnership
  • VYN202 faced FDA partial clinical hold due to testicular toxicity in preclinical studies, but FDA partially lifted hold for female patients with promising preliminary efficacy data
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025All-stock merger agreement with Yarrow Bioscience announced; combined company to trade as YARW
  • November 2025Q3 2025 results: $32.7M cash runway; net loss of $7.3M; R&D spending down 48.7% YoY
  • +2 moreTrack every material event for VYNE Therapeutics Inc. as it happens. Explore monitoring →
Get alerted when VYNE Therapeutics Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Pan-BET InhibitorsCompetitive mechanism class for inflammatory diseases→Topical Inflammatory TreatmentsEstablished market for vitiligo and dermatologic conditions→Oral BD2-Selective BET InhibitorsEmerging mechanism for systemic inflammatory conditions→

Compare VYNE Therapeutics Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

VYNE Therapeutics Inc. operates in Biopharmaceuticals - Immunology & Inflammation / Dermatology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Immunology & Inflammation / Dermatology research →
NEW · MCP server

Ask your AI assistant about VYNE Therapeutics Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare VYNE Therapeutics Inc. and its top competitor on Cyborg Score”
“What did VYNE Therapeutics Inc. do this quarter?”
“Is VYNE Therapeutics Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does VYNE Therapeutics Inc. do?+
VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a to...
What is VYNE Therapeutics Inc.'s Cyborg Score?+
VYNE Therapeutics Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are VYNE Therapeutics Inc.'s main competitors?+
Named competitors include Pan-BET Inhibitors, Topical Inflammatory Treatments, Oral BD2-Selective BET Inhibitors. The full competitive landscape is in the AskCyborg report.
How can I get the full VYNE Therapeutics Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the VYNE Therapeutics Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track VYNE Therapeutics Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.